| Approval
The European Medicines Agency's human medicines committee, the CHMP, adopted a positive opinion on Foundayo (orforglipron), Eli Lilly's GLP-1 pill, at its meeting of October 12 to 15, 2026. EMA published the recommendation on October 16, 2026. The applicant is Eli Lilly Nederland B.V.
The committee recommended it for two uses in adults. The first is weight management, alongside a reduced-calorie diet and more physical activity, in people with a body mass index (BMI) of 30 or higher, or 27 to under 30 with at least one weight-related condition. The second is type 2 diabetes, alongside diet and exercise, as a stand-alone treatment when metformin is not suitable or in combination with other diabetes medicines.
EMA's summary of the evidence cites two studies with 4,740 adults with obesity or overweight, and four main studies with 3,765 adults with type 2 diabetes that compared orforglipron with placebo, dapagliflozin and oral semaglutide. At 72 weeks, weight loss was about 5% to 11%, against about 2% to 2.5% with placebo. In the diabetes studies, HbA1c fell by about 1.2 to 1.9 points. These are EMA's rounded figures.
Worth knowing: A CHMP opinion is a recommendation, not an authorization. The European Commission takes the final decision. As of November 9, 2026, the Atlas has not found a Commission decision, and EMA's Foundayo page still shows the status as a positive opinion. EMA does not say whether the review was standard or accelerated. The UK regulator approved Foundayo separately.
Related: Orforglipron medicine page | Foundayo brand page | Lilly tracker | UK approval | FDA approval
Sources: EMA, meeting highlights from the CHMP, 12 to 15 October 2026 Regulator page. EMA, new oral GLP-1 medicine for weight management and type 2 diabetes Regulator page. EMA, Foundayo medicine page Regulator page.